American Heart Association
Removal of race from MESA score does not affect heart disease risk prediction
CHICAGO — When race was removed from the MESA risk prediction score, its ability to predict risk for heart disease did not change significantly, researchers reported at the American Heart Association Scientific Sessions.
SGLT2s, GLP-1s may improve mortality, CV event risk after stroke
CHICAGO — Use of an SGLT2 inhibitor or GLP-1 receptor agonist after stroke may improve mortality and lower subsequent risk for heart attack and another stroke, a speaker reported.
Cardio-kidney-metabolic syndrome may accelerate CVD risk by up to 28 years
CHICAGO — Elevated risk for heart disease may arrive up to 28 years sooner for individuals with average risk factors plus diabetes and kidney disease vs. those without cardio-kidney-metabolic disease, a speaker reported.
Bystander CPR up to 10 minutes after cardiac arrest still can save a life
CHICAGO — Adults who received bystander CPR within the first few minutes of an out-of-hospital cardiac arrest were much more likely to survive and have better brain function than those who did not, researchers reported.
Yearly lipid fluctuations linked to dementia, cognitive decline in older adults
CHICAGO — High year-to-year cholesterol variability was linked to increased risk for cognitive decline and dementia among older adults, a speaker reported.
Coronary artery disease screening shows no benefit for individuals with diabetes
CHICAGO — Coronary CT angiography screening of asymptomatic adults with diabetes for coronary artery disease did not significantly lower mortality or nonfatal myocardial infarction risk, according to longer follow-up of the FACTOR-64 study.
Fear of recurrence consistent source of stress for heart attack survivors
CHICAGO — Survivors of an acute MI reported fear of a recurrence up to 8 months later, along with high levels of perceived stress that were distinct from depression and anxiety symptoms, researchers reported.
Novel injectable agent lowers Lp(a) by more than 80% at 36 weeks
CHICAGO — Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial.
‘Please talk about it’: Patients with heart disease want more guidance on sexual health
CHICAGO — Results from a new survey highlight a gap between patients’ information needs about sexual health and the actual support provided by health care professionals.
Obicetrapib tied to sizable LDL lowering on top of other therapies in high-risk patients
CHICAGO — In patients with heterozygous familial hypercholesterolemia with high LDL despite being on optimal medical therapy, obicetrapib greatly lowered LDL levels compared with placebo, according to the results of the BROOKLYN trial.